Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Purple Biotech ( (PPBT) ) just unveiled an update.
On September 3, 2025, Purple Biotech announced the expansion of its CAPTN-3 portfolio with the development of IM1305, a novel tri-specific antibody targeting TROP2. This advancement is part of Purple Biotech’s strategy to leverage its CAPTN-3 platform, which aims to overcome the immunosuppressive environment in solid tumors by activating both innate and adaptive immune systems. Encouraging preclinical results have shown sustained tumor regression in various cancer types, highlighting the potential impact of IM1305 on the company’s operations and its positioning within the oncology sector.
The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform.
Purple Biotech’s overall stock score reflects significant financial challenges and unattractive valuation metrics. The absence of revenue and ongoing losses weigh heavily on financial performance. Technical indicators are mixed, with some potential downside risks. The lack of profitability and dividends further contribute to a low valuation score.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to combat tumor immune evasion and drug resistance. The company is advancing its oncology pipeline, which includes the CAPTN-3 platform of tri-specific antibodies, CM24, and NT219. These therapies aim to engage immune responses within the tumor microenvironment, offering novel mechanisms of action against various solid tumors.
Average Trading Volume: 107,878
Technical Sentiment Signal: Sell
Current Market Cap: $6.08M
For detailed information about PPBT stock, go to TipRanks’ Stock Analysis page.